mGluR2 Positive Allosteric Modulators for Neurological Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and psychiatric disorders associated with glutamate dysfunction lack effective modulation of metabotropic glutamate receptors, particularly the mGluR2 receptor, which are implicated in various neurological and psychiatric conditions.
Innovation Solution
Development of 5-substituted 1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide and 1,3-dihydro[1,2,5]thiadiazolo[3,4-b]pyridine 2,2-dioxide derivatives that act as potentiators of metabotropic glutamate receptors, specifically enhancing the response to endogenous glutamate at the mGluR2 receptor without binding to the orthosteric site.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional mGluR agonists are used to treat neurological and psychiatric disorders, then glutamate signaling is activated, but non-specific activation of multiple mGluR subtypes occurs leading to unwanted side effects
Solution Approach 1:
The patent applies local quality by designing compounds that selectively modulate specific mGluR subtypes (particularly mGluR2 and mGluR3) rather than activating all mGluR subtypes non-specifically. The molecular structures are designed with specific pharmacological properties that confer subtype selectivity, allowing therapeutic effects to be achieved at the target receptor while minimizing activation of other receptor subtypes that cause side effects.
Solution Approach 2:
The patent employs parameter changes by modifying the pharmacological parameters of mGluR activation through the development of positive allosteric modulators (PAMs) with distinct binding characteristics. These PAMs bind to allosteric sites rather than the orthosteric glutamate binding site, changing the activation mechanism and enabling selective modulation of specific receptor subtypes with different pharmacological profiles.
2Object-affected harmful factors
If selective mGluR2 agonists are developed to reduce side effects, then subtype selectivity improves, but the complexity of drug discovery and optimization increases
Solution Approach 1:
The patent uses an intermediary approach by developing positive allosteric modulators that bind to allosteric sites on the mGluR2 receptor rather than directly activating the orthosteric glutamate binding site. These PAMs serve as intermediaries that enhance the receptor's response to endogenous glutamate in a selective manner, achieving subtype specificity without requiring direct activation of the canonical binding site, thereby simplifying the structure-activity relationship optimization.
Solution Approach 2:
The patent applies universality by creating a class of compounds (1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide derivatives) that can selectively modulate mGluR2 and mGluR3 receptors across different species and disease models. This multi-functional approach allows a single molecular framework to address multiple indications (schizophrenia, anxiety, depression) through consistent selective mGluR2/mGluR3 modulation, reducing the need for entirely separate drug discovery programs for each indication.
3Reliability
If positive allosteric modulators are used to enhance glutamate response, then receptor sensitivity increases, but the duration of receptor occupancy and signal transduction must be carefully controlled
Solution Approach 1:
The patent applies partial action by designing PAMs that provide moderate to strong potentiation of mGluR2 signaling without causing excessive or prolonged activation. The compounds are optimized to achieve sufficient receptor occupancy and signal transduction enhancement for therapeutic effect while maintaining appropriate kinetic profiles that prevent excessive duration of action, thereby avoiding tolerance development and withdrawal symptoms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively potentiate mGluR2 receptor activity, providing therapeutic benefits for neurological and psychiatric disorders by enhancing glutamate signaling, potentially offering alternative strategies for treating conditions like schizophrenia and anxiety.
Implementation Method 1
These potentiators act by enabling the receptor to produce an enhanced response to endogenous glutamate. Such allosteric potentiators do not bind at the glutamate binding site also known as the 'orthosteric site'
Data Source
AI summary
The present invention is directed to 5-substituted 1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide and 1,3-dihydro[1,2,5]thiadiazolo[3,4-b]pyridine 2,2,-dioxide derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.